A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 225,500 shares of TGTX stock, worth $7.02 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
225,500
Previous 166,100 35.76%
Holding current value
$7.02 Million
Previous $2.95 Million 78.54%
% of portfolio
0.01%
Previous 0.01%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$17.21 - $25.28 $1.02 Million - $1.5 Million
59,400 Added 35.76%
225,500 $5.27 Million
Q2 2024

Aug 14, 2024

BUY
$13.32 - $19.19 $2.21 Million - $3.19 Million
166,100 New
166,100 $2.95 Million
Q3 2023

Nov 14, 2023

BUY
$8.36 - $26.5 $1.83 Million - $5.79 Million
218,600 Added 29.84%
951,200 $7.95 Million
Q2 2023

Aug 14, 2023

BUY
$15.48 - $35.0 $3.24 Million - $7.32 Million
209,000 Added 39.92%
732,600 $18.2 Million
Q1 2023

May 15, 2023

BUY
$10.23 - $19.34 $1.8 Million - $3.41 Million
176,300 Added 50.76%
523,600 $7.87 Million
Q4 2022

Feb 14, 2023

BUY
$5.01 - $11.83 $714,426 - $1.69 Million
142,600 Added 69.66%
347,300 $4.11 Million
Q3 2022

Nov 14, 2022

BUY
$4.57 - $8.4 $252,721 - $464,520
55,300 Added 37.01%
204,700 $1.21 Million
Q2 2022

Aug 15, 2022

BUY
$3.74 - $10.66 $258,434 - $736,606
69,100 Added 86.05%
149,400 $635,000
Q1 2022

May 16, 2022

BUY
$7.81 - $20.45 $627,143 - $1.64 Million
80,300 New
80,300 $764,000
Q1 2021

May 17, 2021

SELL
$41.61 - $54.3 $303,753 - $396,390
-7,300 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$25.27 - $54.9 $184,471 - $400,770
7,300 New
7,300 $380,000
Q2 2019

Aug 14, 2019

SELL
$6.27 - $8.65 $283,404 - $390,980
-45,200 Closed
0 $0
Q1 2019

May 15, 2019

SELL
$4.02 - $8.04 $42,611 - $85,223
-10,600 Reduced 19.0%
45,200 $363,000
Q4 2018

Feb 14, 2019

BUY
$3.44 - $5.76 $44,032 - $73,728
12,800 Added 29.77%
55,800 $229,000
Q3 2018

Nov 14, 2018

SELL
$5.15 - $14.0 $46,865 - $127,400
-9,100 Reduced 17.47%
43,000 $241,000
Q2 2018

Aug 14, 2018

BUY
$12.5 - $15.0 $267,500 - $321,000
21,400 Added 69.71%
52,100 $685,000
Q1 2018

May 15, 2018

BUY
$8.7 - $16.8 $267,090 - $515,760
30,700 New
30,700 $436,000
Q4 2017

Feb 14, 2018

SELL
$7.35 - $12.3 $74,970 - $125,460
-10,200 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$10.0 - $12.7 $102,000 - $129,540
10,200
10,200 $121,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.53B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.